AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WILMINGTON, Del.--(BUSINESS WIRE)--As the AstraZeneca Foundation celebrates its 30th anniversary, the organization has awarded 12 nonprofit organizations $2,170,318 in grants across eight US states and Washington, D.C., for innovative approaches to address healthcare disparities at the community level, a reflection of AstraZeneca's broader commitment to advance health equity efforts. Six grants were awarded through Creating Health Access for Next Generation Equity (CHANGE), its new signature pr.

Astrazeneca Foundation Awards 12 Nonprofit Organizations More Than $2M to Advance Health Equity

AstraZeneca is the best performing pharma in terms of five-year share price growth after Eli Lilly and Novo Nordisk. The latter two companies' valuation growth has been underpinned by a single weight loss / diabetes drug class. AZN is more diversified with a powerhouse oncology division. The oncology division revenues were 17% higher year-on-year in 1H23, while the CVRM division was 14% and rare disease 9%.

AstraZeneca: Hidden Gem Of The Pharma Sector Is A Great Buy Opportunity

Pfizer

Merck

Moderna

CRISPR Therapeutics

GlaxoSmithKline

Novartis

Sanofi

Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA vaccines used in the fight against the Covid-19 pandemic.   The researchers own the patents to the nucleoside modification technology licensed out to drug companies such as BioNTech SE, where Karikó once worked, which developed an mRNA vaccine against Covid-19 with Pfizer Inc (NYSE:PFE), and Moderna Therapeutics Inc (NASDAQ:MRNA).

Nobel for mRNA: Which other biotech stocks might be overlooked?

NVIDIA

Starbucks

The Nasdaq 100 has been absolutely whipsawed in recent years. Two Nasdaq 100 stocks possess the necessary catalysts to fuel double-digit earnings growth.

2 Nasdaq 100 Stocks That Are Surefire Buys in October, and 1 to Avoid Like the Plague

AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.

AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M

The payout will settle the claims of 11,000 people who said they weren't property warned Nexium and Prilosec could cause chronic kidney disease.

AstraZeneca Settles Lawsuits Alleging Heartburn Drugs Caused Kidney Disease For $425 Million

AstraZeneca said it has settled a suite of US legal claims over heartburn treatments Nexium and Prilosec for US$425 million. The UK pharma said the agreements effectively resolve the product liability claims currently pending in the Distinct Court in New Jersey and Superior Courts in Delaware and New Jersey.

AstraZeneca settles Nexium heartburn drug cases for US$425m

British drugmaker AstraZeneca on Tuesday said it will pay $425 million to settle product liability litigations related to acid-reflux medicine Nexium and heartburn drug Prilosec in the United States.

AstraZeneca to pay $425 mln to settle Nexium, Prilosec litigation in US

Bristol-Myers

Novo Nordisk

A federal judge dealt a blow to hopes for a near-term injunction to halt the federal government plan to let Medicare to pay less for a few expensive medicines.

Big Pharma Can't Stop the Price-Negotiation Program. What's Next.

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up.

AstraZeneca (AZN) Key Drugs to Aid Growth, Pipeline Strong

Several major drugmakers, including Merck & Co. Inc. MRK and AstraZeneca PLC AZN, say they're moving forward with the Medicare drug-price negotiation process ahead of this Sunday's deadline to sign agreements to participate–but industry players are also waiting for a key legal ruling that could put the program on pause ahead of that date.

As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment

Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.

Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?

AstraZeneca, Boehringer Ingelheim and other drugmakers have filed at least eight lawsuits seeking to declare the Medicare price talks unconstitutional.

AstraZeneca, Boehringer Ingelheim to participate in Medicare drug price negotiations

AstraZeneca is the largest foreign owned pharmaceutical company in China based on revenue, and they're continuing to increase investment in the country

AstraZeneca Looks To China For Growth - But CEO Says Spinoff Not Happening

AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.

AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study

Morgan Stanley (NYSE:MS) expects the EU biopharma sector to offer a safe haven from weakening growth/higher real yields. “Whilst we continue to favour growth/innovation narratives in biopharma over the long-term, we expect investors to reward earnings upgrade stories - Novo Nordisk, Novartis, AstraZeneca - in the near-term,” it said.

Morgan Stanley sees biopharma sector as a 'safe haven'

AstraZeneca PLC (LSE:AZN)'s assets beyond oncology offer significant upside potential, in the view of investment bank, Jefferies. The broker upgraded the pharmaceuticals giant to 'buy' from 'hold' and increased its price target to 13,000p from 10,500p.

AstraZeneca upgraded on potential for non-oncology assets

AstraZeneca (AZN) ADSs rose after reporting its experimental breast cancer treatment made with Japanese partner Daiichi Sankyo showed positive high-level results in a Phase 3 trial.

AstraZeneca ADSs Rise After Reporting Positive Results in Breast Cancer Drug Trial

AstraZeneca and Daiichi Sankyo said Friday their breast cancer treatment outperformed chemo in a Phase 3 study, and AZN stock jumped.

AstraZeneca Surges To 50-Day Line After Breast Cancer Drug Tops Chemo

AstraZeneca PLC (LSE:AZN)'s share price surged by 2.6%, adding nearly £5 billion to the company's market value, following the announcement of encouraging results from an ongoing clinical trial on datopotamab deruxtecan, a drug aimed at treating breast cancer. The pharma giant reported a "statistically significant and clinically meaningful improvement" in progression-free survival rates compared with traditional chemotherapy treatments.

AstraZeneca breast cancer drug gives drugs giant £5bn boost

AstraZeneca PLC (LSE:AZN) has hailed strong results from an ongoing trial on the effects of drug datopotamab deruxtecan in breast cancer patients. According to the pharmaceutical giant, the drug showed a “statistically significant and clinically meaningful improvement” on progression-free survival when compared with chemotherapy.

AstraZeneca signals strong results from breast cancer drug trial

AstraZeneca said on Friday a drug it is developing with Daiichi Sankyo's to treat patients with a type of breast cancer met one of the main goals in a late-stage study.

AstraZeneca and Daiichi's breast cancer drug meets goal in study

AstraZeneca PLC (LSE:AZN) shares rose 2.4% to 10,868p after its Alexion rare disease unit sealed a deal to buy a portfolio of Pfizer's early-stage drugs to boost its footprint in the burgeoning field of genomic medicine for up to US$1bn. As well as buying and licencing the rare disease gene therapy assets, Alexion has agreed to pay royalties based on levels of potential future sales.

AstraZeneca rises on completion of Pfizer gene therapy deal

Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.

CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer

AbbVie

Currently, the S&P 500 and many sectors are outperforming the healthcare sector, presenting an opportunity to explore assets within this sector during the current period of apathy towards it. AstraZeneca's revenue was $11.42 billion in the second quarter of 2023, up 6% from the prior quarter and beating analysts' consensus estimates by $0.4 billion. At the same time, total sales of AbbVie products continue to decline year over year, amounting to about $13.87 billion for the three months ending June 30, 2023.

News for AstraZeneca Stock (AZN)